Is­raeli biotech flunks PhII liv­er can­cer study, but it in­sists drug Can-Fite dis­ease in sub­set of pa­tients

Is­raeli biotech Can-Fite Bio­Phar­ma is hop­ing to trudge ahead with a late-stage study of its ex­per­i­men­tal can­cer drug, de­spite it fail­ing a mid-stage study in pa­tients with ad­vanced liv­er can­cer.

The drug, namodeno­son, was be­ing test­ed in a 78-pa­tient Phase II study in pa­tients with ad­vanced liv­er can­cer in pa­tients with un­der­ly­ing cir­rho­sis, whose dis­ease had pro­gressed de­spite first­line treat­ment with Bay­er’s Nex­avar.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER